Lymphoproliferative Responses to Recombinant HIV‐1 Envelope Antigens in Neonates and Infants Receiving gp120 Vaccines | Zendy

William Borkowsky | Zendy; Diane W. Wara | Zendy; Terry Fenton | Zendy; James McNamara | Zendy; Minhee Kang | Zendy; Lynne Mofenson | Zendy; Elizabeth J. McFarland | Zendy; Coleen K. Cunningham | Zendy; AnneMarie Duliège | Zendy; Donald Francis | Zendy; Yvonne J. Bryson | Zendy; Sandra Burchett | Zendy; Stephen A. Spector | Zendy; Lisa M. Frenkel | Zendy; Stuart E. Starr | Zendy; Russell Van Dyke | Zendy; Eleanor Jiménez | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Lymphoproliferative Responses to Recombinant HIV‐1 Envelope Antigens in Neonates and Infants Receiving gp120 Vaccines

Author(s) -

William Borkowsky,

Diane W. Wara,

Terry Fenton,

James McNamara,

Minhee Kang,

Lynne Mofenson,

Elizabeth J. McFarland,

Coleen K. Cunningham,

AnneMarie Duliège,

Donald Francis,

Yvonne J. Bryson,

Sandra Burchett,

Stephen A. Spector,

Lisa M. Frenkel,

Stuart E. Starr,

Russell Van Dyke,

Eleanor Jiménez

Publication year - 2000

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/315298

Subject(s) - medicine , immunization , adjuvant , vaccination , lymphoproliferative response , immunology , antigen , heterologous , virology , immune system , immunogenicity , vaccination schedule , biology , peripheral blood mononuclear cell , biochemistry , gene , in vitro

Children of mothers infected with human immunodeficiency virus type 1 (HIV-1) were immunized at birth and at 1, 3, and 5 months with 1 of 3 doses of recombinant gp120 vaccines prepared from SF-2 or MN strains of HIV-1. A total of 126 children were not infected; 21 received adjuvant only. Vaccine recipients developed lymphoproliferative responses on >/=2 occasions, responding more often to homologous HIV-1 antigens than did adjuvant recipients (56% vs. 14%; P<.001). Responses were appreciated after 2 immunizations and were maintained for >84 weeks after the last immunization. An accelerated immunization schedule (birth, 2 weeks, 2 months, and 5 months) with the lowest dose of the SF-2 vaccine produced responses in all 11 vaccinees by 4 weeks. Responses to heterologous envelope antigens were also detected. Immune responses to vaccination are achievable at an age when some infection (perinatal or breast milk exposure related) may be prevented.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research